Related Experiment Video
Updated: Aug 27, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox
Mayuko Amagai1, Sadanori Furudate1, Kentaro Ohuchi1
1Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abstract:
Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare variant of cutaneous T cell lymphoma (CTCL) characterized by CD30-expressing large atypical cells with kidney-shaped nuclei called hallmark cells. Since PCALCL is a rare variant of CTCL, the treatment of PCALCL is still controversial. In this report, a case of PCALCL successfully treated with denileukin diftitox as second-line therapy is described. Interestingly, the administration of denileukin diftitox decreased CD8+ T cells, CD25+ cells, granulysin-bearing lymphocytes, and CD163+ macrophages. The present case suggests that denileukin diftitox might induce an anti-lymphoma effect as well as modulate the tumor microenvironment.

